Stock Events

Takeda Pharmaceutical 

R$80.4
942
+R$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
249.02B
P/E Ratio
14.99
Dividend Yield
3%
Dividend
2.41

Upcoming

Dividends

3%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
-17.82%
1Y Growth
-14%

Earnings

31OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.21
0.02
0.24
0.46
Expected EPS
0.191285672282
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TAKP34.SA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a global pharmaceutical company that competes with Takeda in various therapeutic areas, including oncology and immunology.
Novartis
NVS
Mkt Cap244.75B
Novartis is a multinational pharmaceutical company that competes directly with Takeda in areas such as cardiovascular, oncology, and neuroscience.
Merck
MRK
Mkt Cap300.25B
Merck is known for its strong presence in the pharmaceutical industry, competing with Takeda in oncology, vaccines, and infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Takeda in immunology, neuroscience, and oncology.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes with Takeda in the fields of immunology and oncology, with both companies having significant investments in research and development.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline competes with Takeda in respiratory, vaccines, and infectious disease, with a strong focus on research and development.
Sanofi
SNY
Mkt Cap141.43B
Sanofi competes with Takeda in areas such as immunology, oncology, and rare diseases, with a broad portfolio of products.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb competes with Takeda in oncology and cardiovascular diseases, with both companies focusing on innovative treatments.
Roche
RHHBY
Mkt Cap272.83B
Roche, through its pharmaceutical division, competes with Takeda in oncology, immunology, and infectious diseases, with a strong emphasis on biologics.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca competes with Takeda in several key areas including oncology, cardiovascular, and respiratory diseases, with a focus on innovation and targeted therapies.

About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Show more...
CEO
Mr. Christophe Weber
Employees
47347
Country
JP
ISIN
BRTAKPBDR006

Listings